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We have investigated the mechanism of interferon (IFN) induction in peripheral blood mononuclear cells by HIV-1(IIIB)-
infected H9 cells or by recombinant gp120. A monoclonal antibody specific for the galactosylsphingosinyl moiety in galactoce-
rebrosides and sulfatides inhibited IFN induction in a dose-dependent manner. Furthermore, exogenous sulfatides inhibited
with an ID50 of approximately 1 mM, whereas galactocerebrosides were not inhibitory at 40 times higher concentrations.
These studies suggest that sulfate containing galactolipids such as sulfatides on responder cells may be part of the gp120–
membrane complex that initiates the induction of IFN. A partial homology of an epitope on the V3 loop of gp120 with a
previously suggested binding domain for sulfated glycoconjugates supports this conclusion. q 1996 Academic Press, Inc.
INTRODUCTION gp120 we found that interaction of gp120 with the CD4
antigen on the responder cells was necessary, but not
Interferons (IFNs) are responsible for early host de-
sufficient, for IFN induction. MABs that recognize the V3
fenses against many viral infections. In cultured cells
loop of gp120, but do not interfere with CD4 binding of
IFNs block replication of HIV, and in HIV-infected patients
gp120, also completely inhibited IFN induction, indicatingIFN-a treatment suppresses Kaposi sarcoma, one of the
an important role of V3 in the induction phenomenoncalamities of AIDS (Yamamoto et al., 1986; Hartshorn et
(Ankel et al., 1994). Similar results were obtained whenal., 1987; Lane et al., 1988; Poli et al., 1989; Sperber et
intact HIV-1 or HIV-1-infected cells were used as IFNal., 1992; Shirazi and Pitha, 1992). IFNs a and g have
inducers (Francis and Meltzer, 1993). These data suggestbeen demonstrated in the circulation of AIDS patients,
that gp120, in order to induce IFN, has to interact withand both IFNs were produced when cultured peripheral
two separate membrane sites: the gp120-binding domainblood mononuclear cells (PBMC) were incubated with
on CD4, which is well defined, and another unknown siteHIV-1 or HIV-1-infected cells (Capobianchi et al., 1988,
that recognizes the V3 loop.1992a; Rinaldo et al., 1990; Toso et al., 1990; Szebeni et
Despite its specificity for the CD4 antigen, HIV-1 alsoal., 1991; Francis and Meltzer, 1993; Ferbas et al., 1994;
infects CD4-negative cells of brain and intestinal originGhanekar et al., 1995). Inactivation by chemical cross-
(Harouse et al., 1991; Bhat et al., 1991; Yahi et al., 1992).linking did not abrogate the IFN-inducing potential of
In these cells the galactose-containing glycolipids galac-HIV-1-infected cells, indicating that induction is not de-
tocerebrosides (Gal-cer) and (or) sulfatides (Sulf-galcer)pendent on viability or replication of the virus (Capobian-
appeared to function as alternate receptors. MABs rec-chi et al., 1988). Furthermore, recombinant versions of
ognizing galactocerebrosides and sulfatides blockedthe HIV-1(IIIB) viral envelope glycoprotein gp120 and its
HIV-1 infection, and permissiveness for HIV-1 infectionprecursor, gp160, are potent IFN inducers in the com-
correlated with the expression of galactocerebrosidesplete absence of other viral components (Capobianchi
on the cell surface of CD4-negative HT29 clones andet al., 1992b; Ankel et al., 1994). IFN induced by HIV-1-
neuronal cells (Harouse et al., 1991; Bhat et al., 1991;infected cells or by recombinant gp120 is mainly of the
Yahi et al., 1992; Fantini et al., 1993). Also, HIV-1-nonper-a type containing small amounts of IFN-g (Capobianchi
missive human lymphoblastoid U729 cells not express-et al., 1992a, 1993). ELISA assays of several gp120-in-
ing surface galactocerebrosides were unable to bindduced PBMC culture supernatants indicated an Interna-
gp120. However, concomitant with membrane uptake oftional Unit (IU) ratio of IFN-a/IFN-g of approximately 5/1
exogenous sulfatides, specific gp120 binding was clearly(Ameglio et al., 1994). Employing soluble CD4 or mono-
demonstrable by immunofluorescence (McAlarney et al.,clonal antibodies (MABs) specific for various epitopes of
1994). In in vitro binding studies using liposomes, thin-
layer chromatography (TLC) overlay, or ELISA assays,1 To whom reprint requests should be addressed at Department of
recombinant gp120 specifically bound to galactocerebro-Biochemistry, Medical College of Wisconsin, P.O. Box 26509, Milwau-
kee, WI 53226. Fax: (414) 266-8497. sides and sulfatides, but not to glucosyl- or lactosylcera-
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mides (Harouse et al., 1991; Bhat et al., 1991; Yahi et heat-inactivated fetal bovine serum (FBS). For antiviral
assays by virus yield reduction, A549 cell monolayers inal., 1992; van den Berg et al., 1992; Fantini et al., 1993;
McAlarney et al., 1994). Binding was inhibited by a panel 96-well microtiter plates were preincubated overnight
with IFN-containing cell supernatants. They were thenof monoclonal anti-V3 antibodies and by multimeric
branched peptide constructs (mbpc) of the V3 consensus infected with encephalomyocarditis virus (EMC) and end
points were determined by inspection of ensuing cyto-motifs GPGRAF or RKSIHIGPGRAFYT (Cook et al., 1994;
Yahi et al., 1995). The same constructs blocked HIV-1 pathic effects 24 hr thereafter (Jameson et al., 1977). A
laboratory reference of IFN-a, standardized to the NIH Gainfection not only in CD4-negative HT29 cells, but also
in CD4-positive CEM cells or macrophages (Yahi et al., 023-902-530 reference, was used as internal standard.
Chronically HIV-1(IIIB)-infected H9 cells were routinely1994). This suggests that interaction of the V3 domain
of gp120 with galactose-containing glycosphingolipids is propagated in RPMI medium with 10% FBS. For use as
IFN inducers they were treated with 0.025% glutaralde-not restricted to the infection of CD4-negative cells. In
the work presented here we describe our observations hyde in PBS for 30 min at 47, then washed two times
with PBS and suspended in PBS to 4 1 106 cells/ml andwhich suggest that sulfatides or structurally related gly-
colipids may also have a functional role in the induction stored at 47 until used. The IFN-inducing potential of
these cells was stable up to 6 weeks of storage at 47,of IFN-a by HIV-1.
but declined thereafter. PBMC from donors negative for
MATERIALS AND METHODS HIV and hepatitis B virus were isolated from fresh buffy
Materials coats obtained from the blood bank of the Polyclinic of
La Sapienza University (Rome). Centrifugation on Ficoll–Recombinant gp120 from HIV-1(IIIB) was produced in
Hypaque gradients was routinely used to isolate PBMC.a baculovirus expression system and was obtained from
Cells were suspended in RPMI medium containing 10%American BioTechnologies (Cambridge, MA; now Intra-
FBS and kept on ice until used. All induction experimentscel). It was ⁄90% homogeneous by analysis of Coomas-
employed PBMC on the same day the blood was drawn.sie blue-stained SDS–PAGE. The numbering of its amino
acid residues was that for the processed glycoprotein
lacking the leader sequence (Capon and Ward, 1991). IFN induction and inhibition of induction
Mixed galactocerebrosides from bovine brain (substi-
Freshly isolated PBMC (2 1 106 cells/ml) were incu-tuted to 50–60% with a-hydroxy fatty acids and to 40–
bated in duplicates at 377 in 0.1 ml RPMI/10% FBS con-50% with non-hydroxy fatty acids), type I galactocerebro-
taining constant amounts of inducers and inhibitors atsides (substituted to 98% with a-hydroxy fatty acids), glu-
varying concentrations. After overnight incubation the re-cocerebrosides (Glu-cer), sulfatides, psychosine (b-ga-
action mixtures were centrifuged and supernatants col-lactosylsphingosine) and 3-(4,5-dimethylthiazol-2-yl)-2,5-
lected and titrated in duplicates or quadruplicates ondiphenyltetrazolium bromide (MTT) were obtained from
A549 cells using EMC as indicator virus. Storage of su-Sigma Chemical Co. (St. Louis, MO). The mouse MAB-
pernatants at0207 did not significantly change their anti-GalC was from Boehringer Mannheim GmbH. This anti-
viral titers, thus retitrations of frozen supernatants couldbody binds galactocerebrosides and psychosine equally
be done to confirm previous titrations. In inhibition stud-well and cross-reacts with sulfatide with a 16-fold lower
ies using MAB-GalC, PBMC and antibody were preincu-titer. It is unreactive with glucocerebrosides, ceramide,
bated at 377 for 30 min before the inducer was added.sphingosine, and mixed brain gangliosides (Ranscht et
Reversal of MAB-GalC-generated inhibition by psy-al., 1982). The multibranched peptide construct (GPG-
chosine was shown as follows. Antibody at 20 mg/ml wasRAF)8-K4-K2-K-bA (GPGRAF-mbpc) was synthesized by
incubated with 50 mg/ml of the glycolipid in 50-ml volumeautomated solid-phase peptide synthesis starting with
for 20 min at 377. Thereafter PBMC in RPMI/10% FBSFmoc8-K4-K2-K-bA-NovaSyn-KA resin (Calbiochem–No-
were added so that a cell concentration of 2.8 1 106vabiochem, San Diego CA) as previously described (Yahi
cells/ml and an antibody concentration of 7 mg/ml re-et al., 1994, 1995). This material blocked replication of
sulted, and incubation at 377 was continued for anotherHIV-1(IIIB) in C8166 cells with a 50% inhibitory dose (ID50)
20 min. H9 cells were then added to a final ratio ofof approximately 0.1 to 0.3 mM (C. Castilletti and F.
inducer cells/PBMC of 1/12.5, followed by overnight incu-Frezza, unpublished data). Its cytotoxic dose, determined
bation at 377. Control reaction mixtures without antibody,by MTT assay in C8166 cells, was 30 mM and 50 mM
psychosine, or either were handled identically. Antiviralin PBMC (Denizot and Lang, 1986). It was synthesized
titrations in supernatants of the incubation mixtures wereat the Protein and Nucleic Acid Shared Facility of the
carried out as described above. When inhibition by glyco-Medical College of Wisconsin (Milwaukee, WI), Dr. Liane
lipids was analyzed, reaction mixtures containing gp120Mende-Mueller, Director.
and glycolipid were preincubated for 15 min at room
Cells and virus temperature before PBMC were added. Stock solutions
of glycolipids in methanol were made by warming to 607Human A549 cells were routinely cultured in Dulbec-
co’s modified minimal essential medium containing 10% in a water bath until clear solutions resulted. From these
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FIG. 1. Induction of IFN by cross-linked HIV-infected H9 cells and inhibition of induction by MAB-GalC. Chronically HIV-1(IIIB)-infected H9 cells
were treated with glutaraldehyde as described under Materials and Methods, then added to 2 1 106 PBMC/ml at the indicated ratios (A) or at a
ratio of 1:10 (B). (A) Induction of IFN is 12 maximal at a cellular ratio of inducer cells to PBMC of approximately 1:5 and still measurable at an
approximate ratio of 1:50. (B) MAB concentration-dependent inhibition of IFN induction, when PBMC are preincubated with MAB-GalC at indicated
concentrations prior to the addition of the H9 inducer cells. As seen, 50% inhibition of induction occurs after preincubation with approximately 5
mg/ml MAB. All assays were done in quadruplicates and bars indicate standard deviations. Control antiviral activity (100%) was 1280 IU/ml. Control
cells consisting of glutaraldehyde-treated uninfected parent cells of H9 cells (HT cells) did not cause induction of antiviral activity under conditions
comparable to those used with H9 cells (see also Capobianchi et al., 1988).
stocks predilutions were made in RPMI/10% FBS, and decreased IFN levels to 16% of control levels, consistent
with the data shown in Fig. 1. However, prior incubationappropriate aliquots were then transferred to individual
reaction mixtures. Identical dilutions of methanol served of the antibody with psychosine blocked its action, so
that in this case threefold higher IFN levels resulted (Pas controls. The GPGRAF-mbpc was dissolved in PBS
and aliquots were preincubated with inducer gp120 or  0.007). The observed reversal of the inhibitory effects
of MAB-GalC by psychosine is compatible with the ob-HIV-1-infected and cross-linked H9 cells in RPMI/10%
FBS for 15 min at room temperature prior to the addition servations that the MAB has greater affinity for Gal-cer
and psychosine than for Sulf-galcer (Rantscht et al.,of PBMC. Methanol, the oligopeptide, and the glycolipids
were all nontoxic to the PBMC at the concentrations 1982), and that gp120(IIIB) has greater affinity for Sulf-
galcer than for Gal-cer (Van den Berg et al., 1992; McAlar-employed in the experiments, as judged from trypan blue
exclusion assays. ney et al., 1994).
Since the inducing part of HIV-1-infected H9 cells is
RESULTS the surface-expressed viral glycoprotein gp120 (Francis
and Meltzer, 1993), we directly tested the effect of MAB-Effects of a galactosylsphingosine-specific MAB
GalC on IFN induction by recombinant gp120. As shown
Previous work had shown that glutaraldehyde-treated in Fig. 2A, in the absence of the MAB half-maximal IFN
HIV-1-infected cells were effective inducers of (mainly)
IFN-a in PBMC from healthy individuals (Capobianchi et
al., 1988; 1992a). When we incubated PBMC with such TABLE 1
cells, increasing antiviral activity was produced with 12 Effect of Psychosine on MAB-GalC-Dependent Inhibition of IFN
maximal induction at an approximate effector cell/PBMC Induction by HIV-1-Infected H9 Cells
ratio of 1/5 (Fig. 1A). When the PBMC were preincubated
Additionwith MAB-GalC, which recognizes b-galactosylsphingo-
sine in galactocerebrosides, sulfatides, and psychosine,
H9 IFN titer
subsequent IFN induction decreased and became 90% Sample Psychosine MAB cells [IU/ml] %
inhibited by 10 mg/ml antibody (Fig. 1B).
A 0 0 / 2240 { 640 100That the effect of MAB-GalC was due to its specificity
B / 0 / 2560 { 0 114for b-galactosylsphingosine was shown by reversing the
C 0 / / 360 { 200 16inhibition with psychosine, as described under Materials
D / / / 1120 { 320 50
and Methods. As shown in Table 1 psychosine at a final
concentration of 17 mg/ml had no inhibitory effect on IFN Note. Experimental conditions are those described under Materials
and Methods. The ratio of H9 cells to PBMC was 1:12.5.induction by H9 cells, whereas MAB-GalC at 7 mg/ml
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FIG. 2. Induction of IFN by recombinant gp120 and inhibition of induction by MAB-GalC. (A) Indicated amounts of recombinant gp120 were added
to 2 1 106 PBMC/ml. (B) The final gp120 concentration was 1 mg/ml. As seen in A, half-maximal induction of IFN occurred at approximately 0.7 mg/
ml or 6 nM gp120, consistent with earlier observations (Ankel et al., 1994). B shows MAB concentration-dependent inhibition of IFN induction, when
PBMC are preincubated with MAB-GalC at indicated concentrations prior to the addition of the inducer. As seen, 50% inhibition of induction can
be extrapolated to occur after incubation with approximately 4 mg/ml MAB. Bars indicate standard deviations. Control antiviral activity (100%) was
320 IU/ml.
induction occurred at approximately 6 nM gp120 (0.7 mg/ ing glycolipids employed under similar conditions, up to
the concentrations indicated: glucocerebrosides (40 mg/ml), which is close to the dissociation constant of the
gp120/CD4 complex (4 nM; Ref. Lasky et al., 1987). When ml), galactocerebroside mixtures (40 mg/ml), galactocere-
brosides type I (40 mg/ml), psychosine (17 mg/ml). Nonethe PBMC were preincubated with increasing concentra-
tions of MAB-GalC, subsequently produced IFN levels of these glycolipids were inhibitory at comparable con-
centrations, when HIV-1-infected H9 cells were used asdiminished and were 90% inhibited at approximately 10
mg/ml of the antibody (Fig. 2B). inducers. Surprisingly, sulfatides also did not inhibit in
this case for unknown reasons.These data further support the conclusion that b-ga-
lactosylsphingosine containing glycolipids on the re-
sponder cells are important for IFN induction by gp120.
Effects of octameric branched GPGRAF-mbcp
Effects of exogenous glycolipids
We had previously observed that a synthetic peptide
spanning the entire V3 loop sequence of HIV-1(IIIB) (resi-Since in in vitro binding studies (Harouse et al., 1991;
dues 266–302) or a partial sequence from its middleBhat et al., 1991; Yahi et al., 1992; van den Berg et al.,
portion (residues 272–291) inhibited IFN induction by1992; McAlarney et al., 1994; Cook et al., 1994; Yahi et
recombinant gp120, resulting in 50% inhibition at 4 andal., 1995) recombinant gp120 directly interacted with ga-
5 mM, respectively (Ankel et al., 1994). Octapeptide se-lactolipids, we investigated whether exogenous glycolip-
quences containing the GPGRAF motif of the apex ofids would be inhibitory when added to IFN induction
the V3 consensus sequence (QRGPGRAF, GPGRAFVT),mixtures containing gp120 as the inducer. As shown in
however, were not inhibitory up to 50 mM. Previous workFig. 3 increasing amounts of sulfatides progressively de-
by others had shown that in contrast to the linear syn-creased production of antiviral activity in response to
thetic hexapeptide GPGRAF, an octameric branched pep-recombinant gp120. Shown are two separate experi-
tide construct, GPGRAF-mbpc, inhibited HIV-1 infectionments with PBMC from two unrelated donors. The con-
of PBMC with an ID50 of 0.05 mM and HIV-1-induced cellcentration dependence of inhibition by the glycolipid is
fusion at 0.5 mM (Yahi et al., 1994). We investigatedvery similar in both experiments and extrapolates to 0.7 –
whether inhibition of HIV-1-dependent IFN induction1.0 mg/ml for 50% inhibition of induction, or approximately
could also be blocked by this mbpc construct. However,1 mM (assuming a sulfatide structure uniformly substi-
although the octameric peptide construct synthesized intuted with palmitate). Vehicle alone or vehicle plus sul-
our facility was very potent in inhibiting HIV-1(IIIB) repli-fatides had no cytotoxic effects when added to control
cation in C8166 cells (ID50 of approximately 0.1 to 0.3incubations at comparable concentrations, nor did sul-
mM), it inhibited IFN induction by infected H9 cells or byfatides at the concentrations used interfere with subse-
gp120 only at 100-fold higher concentrations (data notquent interferon assays on A549 cells.
No consistent inhibition was observed with the follow- shown).
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1994). Yet binding to Gal-cer was clearly seen when
assays based on TLC overlays or liposomes were used
(McAlarney et al., 1994; Long et al., 1994). It seems likely
that the presence of exogenous Gal-cer is without conse-
quence for IFN induction due to a much higher affinity
of gp120 for sulfatides compared to Gal-cer, as was ob-
served in the ELISA binding assays referred to above.
However, secondary effects related to differences in mi-
cellar conformations of both types of glycolipids in our
assay conditions cannot be excluded.
The apex of the V3 loop of gp120(IIIB) contains the
hexapeptide sequence GPGRAF which is conserved in
most HIV-1 isolates from North American and European
subjects (Myers et al., 1994). Inhibition of HIV-1 infection
of cultured cells by less than micromolar concentrations
of oligolysine-bound branched peptide constructs con-
taining this sequence has been described (Cook et al.,
1994; Yahi et al., 1995). These constructs also inhibited
binding of gp120 to Gal-cer in TLC overlay assays, albeit
at much higher concentrations. We found little inhibition
of IFN induction by an octameric branched peptide con-
FIG. 3. Inhibition of gp120-dependent IFN induction by sulfatides. struct of GPGRAF, although the anti-HIV-1 potency of our
gp120 at 1 mg/ml was preincubated with sulfatides at the indicated construct was comparable to that originally described
concentrations for 15 min at room temperature, prior to the addition of
(ID50 approximately 0.1–0.3 mM). It is possible that thePBMC to 2 1 106 cells/ml. IFN titrations were carried out in quadrupli-
site on IFN-producing cells that reacts with the V3 loopcates and bars indicate standard deviations. Shown are the effects of
sulfatides in two separate experiments using PBMC from two unrelated of gp120 relies on sequences beyond the GPGRAF motif
donors. As seen, 50% inhibition of induction can be extrapolated to of gp120 and includes residues on the N- and (or) the
occur at approximately 0.7 mg/ml (experiment 1) and 1.0 mg/ml (experi- C-terminus of GPGRAF. In this context it is striking that
ment 2). Control antiviral activity (100%) was 320 IU/ml in both experi-
the V3 loop sequence of HIV-1(IIIB) on the carboxyl sidements.
of GPGRAF shows homology with a previously postulated
sulfatide-binding domain, as indicated in Fig. 4 (Holt et
DISCUSSION
al., 1989). The cells that produce IFN-a in response to
HIV-1 are primarily dendritic cells, which represent a mi-The present investigation was prompted by in vitro
findings of direct and specific binding of gp120 to galac- nor subpopulation of PBMC (Ferbas et al., 1994). These
cells express the CD4 antigen, but their membrane glyco-tocerebrosides and sulfatides (Harouse et al., 1991; Bhat
et al., 1991; van den Berg et al., 1992; Yahi et al., 1992, lipid pattern is presently unknown (Ferbas et al., 1994;
O’Doherty et al., 1993). Analysis of the glycolipid pattern1995; Fantini et al., 1993; McAlarney et al., 1994; Cook
et al., 1994). We found that IFN induction by HIV-1-in- of these cells would provide more definite clues for iden-
tifying those that play a specific role in IFN induction.fected cells and by its glycoprotein gp120 can be blocked
by a MAB specific for the galactosylsphingosine residue The mechanism of IFN-a induction by HIV-1 gp120 is
presently undefined. We previously suggested that inter-on cerebrosides, sulfatides, and psychosine. As inhibi-
tion by the MAB was decreased by the hapten b-galacto- action of gp120 with its binding site on CD4 served as
an anchor to IFN-producing cells, to allow for subsequentsylsphingosine, the effect is, indeed, the consequence
of the MAB’s specificity. It should be pointed out that it interaction with a V3 loop-specific ‘‘secondary receptor’’
(Ankel et al., 1994). It is possible that sulfatides or relatedwas the same MAB-GalC that inhibited HIV-1 infection
of colonic epithelial HT29 cells and of primary endothelial galactocerebrosides would not only serve as secondary
attachment sites, but would also participate actively incells (Yahi et al., 1992; Scheglovitova et al., 1993). Also,
in support of the antibody data, preincubation of gp120 transmembrane signaling. Sulfatides can trigger in-
creases of cytosolic calcium ions and enhanced mRNAwith sulfatides reproducibly blocked IFN induction, yield-
ing 50% inhibition at approximately 1 mM concentration. expression for TNF-a and IL-8 in human neutrophils (Lau-
danna et al., 1994). Ceramides, the lipid constituents ofHowever, no inhibition was seen with Gal-cer, Glu-cer,
or psychosine, when used under comparable conditions. glycolipids and sphingomyelins, have been implicated
as signal transducers in the action of the cytokines TNF-In in vitro studies binding of gp120 to galactocerebro-
sides depended on the experimental conditions: In ELISA a and IL1-b (Ballou, 1992; Hannun, 1994). In human fibro-
blasts IL1-b stimulated the accumulation of ceramidesplates or on nitrocellulose paper gp120 from HIV-IIIB
specifically bound to sulfatides, but poorly to galactoce- through breakdown of sphingomyelin, and ceramides, in
turn, induced IL6 gene expression (Ballou et al., 1992;rebrosides (Van den Berg et al., 1992; McAlarney et al.,
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FIG. 4. Partial sequence homology between the V3 loop of gp120(IIIB) and a proposed binding domain for sulfated glycoconjugates (Holt et al.,
1989). Vertical lines represent homologous amino acids. X and dotted lines indicate nonconserved amino acids. The asterisk represents a spacing
introduced for optimal alignment.
envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 88, 7131–Laulederkind et al., 1995). Since incubation of PBMC with
7134.gp120 also causes increased levels of IL1-a, IL1-b, and
Capobianchi, M. R., De Marco, F., DiMarco, P., and Dianzani, F. (1988).
IL6, a similar mechanism involving ceramide transduc- Acid-labile human interferon alpha production by peripheral blood
tion could have caused modulation of these and other mononuclear cells stimulated by HIV-infected cells. Arch. Virol. 99,
lymphokines including IFN-a (Ameglio et al., 1994). Fur- 9–19.
Capobianchi, M. R., Mattana, P., Mercuri, F., Conciatori, G., Ameglio,thermore, activation of transcription factor 1 (AP-1) in
F., Ankel, H., and Dianzani, F. (1992a). Acid lability is not an intrinsicCD4-positive cells by both gp120 and gp160 has been
property of interferon-a induced by HIV-infected cells. J. Interferondescribed, and activation of membrane-bound protein ki-
Res. 12, 431–438.
nases and phosphatases by ceramide has been demon- Capobianchi, M. R., Ankel, H., Ameglio, F., Paganelli, R., Pizzoli, P. M.,
strated (Raines et al., 1993; Dobrowsky et al., 1993; Chir- and Dianzani, F. (1992b). Recombinant glycoprotein 120 of human
immunodeficiency virus is a potent interferon inducer. AIDS Res.mule et al., 1995). Thus, induction of IFN-a (and of other
Hum. Retroviruses 8, 575–579.lympho- and cytokines) could be the consequence of
Capobianchi, M. R., Ameglio, F., Fei, C. P., Castilletti, C., Mercuri, F.,uncontrolled stimulation of galactosyl cerebroside or cer-
Fais, S., and Dianzani, F. (1993). Coordinate induction of interferon
amide release from membrane sulfatides after their inter- a and g by recombinant HIV-1 glycoprotein 120. AIDS Res. Hum.
action with HIV-1 or its gp120. A membrane-associated Retroviruses 9, 957–962.
Capon, D. J., and Ward, R. H. R. (1991). The CD4–gp120 interactionsulfatide sulfatidase distinct from lysosomal arylsulfa-
and AIDS pathogenesis. Annu. Rev. Immunol. 9, 649–678.tases could be involved in such a scenario (Sundaram et
Chirmule, N., Goonewardena, H., Pahwa, S., Pasieka, R., Kalyanaraman,al., 1995). However, whether sulfatide–gp120 interaction
V. S., and Pahwa, S. (1995). HIV-1 envelope glycoproteins induce
does, indeed, result in the modification of cellular cere- activation of activated protein-1 in CD4/ T cells. J. Biol. Chem. 270,
broside or ceramide pools, remains to be determined. 19364–19368.
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